Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Caplin Point Laboratories's
Operating Income
for the
three
months ended in Mar. 2026 was ₹1,854 Mil. Caplin Point Laboratories's Interest Expense for the
three
months ended in Mar. 2026 was ₹-4 Mil.
Caplin Point Laboratories's interest coverage for the quarter that ended in Mar. 2026 was 515.11.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Caplin Point Laboratories Ltd has enough cash to cover all of its debt. Its financial situation is stable.
The historical rank and industry rank for Caplin Point Laboratories's Interest Coverage or its related term are showing as below:
NSE:CAPLIPOINT'
s Interest Coverage Range Over the Past 10 Years
Min: 184.48 Med: 753.99 Max: 3479.13
Current: 781.92
NSE:CAPLIPOINT's Interest Coverage is ranked better than 91.96% of 684
companies
in the Drug Manufacturers industry
Industry Median: 12.765
vs NSE:CAPLIPOINT: 781.92
Caplin Point Laboratories (NSE:CAPLIPOINT) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Caplin Point Laboratories Interest Coverage Related Terms
Caplin Point Laboratories Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
NSE:CAPLIPOINT vs ZTS, UTHR: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Caplin Point Laboratories's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Caplin Point Laboratories Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Caplin Point Laboratories's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Caplin Point Laboratories's Interest Coverage falls into.
Caplin Point Laboratories Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Caplin Point Laboratories (NSE:CAPLIPOINT) has a Interest Coverage of 515.11 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Caplin Point Laboratories and its competitors. This is 32% below median its historical median of 753.99. Over the past decade, Caplin Point Laboratories' Interest Coverage has ranged from 184.48 to 3,479.13. According to the industry distribution chart, Caplin Point Laboratories ranks #55 out of 684 companies in the Drug Manufacturers industry, placing it in the top 8%.
Is Caplin Point Laboratories' Interest Coverage too high?
Caplin Point Laboratories' current Interest Coverage of 515.11 is 32% below median its 10-year median of 753.99. Over the past 10 years, this metric has ranged from a low of 184.48 to a high of 3,479.13. The Drug Manufacturers industry median Interest Coverage is 12.77. Caplin Point Laboratories' value of 515.11 is 3935.3% above this industry median. Based on the distribution chart, Caplin Point Laboratories ranks #55 out of 684 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Caplin Point Laboratories has a GF Score™ of 89/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Caplin Point Laboratories' Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Caplin Point Laboratories ranks #55 out of 684 companies for Interest Coverage. This places Caplin Point Laboratories in the top 8% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 12.77. Caplin Point Laboratories' value of 515.11 is 3935.3% above this benchmark. Historically, Caplin Point Laboratories' own Interest Coverage has ranged from 184.48 to 3,479.13 over the past decade. While the company's 10-year median is 753.99 vs. the industry median of 12.77, Caplin Point Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.77, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Caplin Point Laboratories's current Interest Coverage of 515.11 is 3935.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Caplin Point Laboratories and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Caplin Point Laboratories's current Interest Coverage is 515.11, which is 32% below median its own 10-year median of 753.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Caplin Point Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Caplin Point Laboratories (NSE:CAPLIPOINT) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,073.29, compared to a current price of ₹2,506.40 — trading 20.9% above its estimated fair value. The current Interest Coverage is 515.11, which is 32% below median its 10-year median of 753.99 and 3935.3% above the Drug Manufacturers industry median of 12.77. Caplin Point Laboratories' overall GF Score™ is 89/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Caplin Point Laboratories (NSE:CAPLIPOINT), the current Interest Coverage is 515.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Caplin Point Laboratories (NSE:CAPLIPOINT) Overvalued in 2026?
Based on GuruFocus' analysis, Caplin Point Laboratories stock appears to be overvalued.
The current stock price of ₹2,506.40 is trading 20.9% above its estimated GF Value™ of ₹2,073.29.
GuruFocus considers Caplin Point Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:CAPLIPOINT:
Interest Coverage: 515.11 (32% below median its 10-year median of 753.99)
GF Value™: ₹2,073.29 vs. price of ₹2,506.40 (20.9% above fair value)
Industry Position: 3935.3% above the Drug Manufacturers median (#55 of 684)
No single metric tells the full story. See the NSE:CAPLIPOINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Caplin Point Laboratories Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and marketing of pharmaceutical products. The company's key products include tablets, capsules, injections (liquid and lyophilized, prefilled syringes), ophthalmic solutions, liquid orals, soft gel capsules, ointments, creams, gels, powders for injections, suppositories, ovules, pre-mix bag formulations, inhalers, sprays, and IV infusions. It also provides pharmaceutical formulations in specialized injectable dosage forms and Ophthalmic drops.
89GF Score
Get the complete analysis for NSE:CAPLIPOINT
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CAPLIPOINT has been successfully added to your 
